Professor Dame Pamela J ShawPam_Shaw

DBE MBBS MD FRCP FMedSci FAAN FANA FAAAS

Department of Neuroscience
Sheffield Institute for Translational Neuroscience
University of Sheffield
385 Glossop Road
Sheffield S10 2HQ
UK

Tel: +44 (0)114 22 28714
or +44 (0)114 22 22295
Email: : pamela.shaw@sheffield.ac.uk

Academic Secretary: Laura Haslam
Tel: +44 (0)114 22 28714
Email: l.haslam@sheffield.ac.uk

Clinical Secretary: Erica Waines
Email: Erica.Waines@sth.nhs.uk
Tel: +44 (0)114 271 3188

Current Positions

  • Vice President and Head of the Faculty of Medicine and Dentistry, University of Sheffield
  • Professor of Neurology, University of Sheffield
  • Director, Sheffield Institute for Translational Neuroscience (SITraN)
  • Director, NIHR Biomedical Research Centre Translational Neuroscience for Chronic Neurological Disorders
  • Director, Sheffield Care and Research Centre for Motor Neuron Disorders
  • Consultant Neurologist, Sheffield Teaching Hospitals NHS Foundation Trust

Biography

Professor Shaw graduated in Medicine with 1st Class Honours from the University of Newcastle in 1979. She undertook her MRCP and Specialist Training in Neurology training in Newcastle. In 1988 she was awarded an MD with commendation for her work on the neurological complications of coronary bypass surgery. After an intermediate fellowship award from the Wellcome Trust, she was awarded a Wellcome Senior Fellowship in Clinical Science which she held from 1991 -2000. In 1997 she was appointed Professor of Neurological Medicine at the University of Newcastle and in 2000 was appointed as Professor of Neurology at the University of Sheffield.

As an undergraduate in Newcastle she was awarded the Stephen Scott; Gibb; Mary Gordon; Mona McNaughton and Phillipson Prizes/Scholarships and achieved distinction in all undergraduate examinations.

Postgraduate Awards

  • 2017 Honorary Degree, University of Bradford for internationally recognized work in the field of Neurology and instrumental work in setting standards of excellence in the clinical care for patients.
  • 2017 Honorary Doctor of Medicine, University of Sussex in recognition of major contribution to the field of Neurology.
  • 2017 University of Sussex Brain Visiting Professorship
  • 2017 Kosterlitz Lecture, University of Aberdeen.
  • 2016 Croonian Lecture, UK Royal College of Physicians
  • 2015 Osler Lecture, Association of Physicians of the United Kingdom and Ireland
  • 2015 Elected Fellow of the American Association for the Advancement of Science for groundbreaking basic and translational research of relevance to the understanding and treatment of neurodegenerative diseases.
  • 2014 Dame Commander of the Order of the British Empire (DBE) for services to Neuroscience
  • 2014 Jacobson Visiting Professorship, University of Newcastle upon Tyne
  • 2013 Alfred Meyer’s Memorial Award Lecture British Neuropathological Society
  • 2013 NIHR Senior Investigator Award
  • 2013 UK ACCEA Platinum Clinical Excellence Award
  • 2012 Gary and Peggy Edwards Distinguished Visiting Professorship for ALS, Houston USA
  • 2012 Elected President of the North of England Neurological Association
  • 2012 Visiting Professorship, Association of Physicians (Kerala Chapter) India
  • 2012 Elected to membership of the Medical Pilgrims
  • 2007 The International ALS/MND Forbes Norris Award for excellence in research and compassion in clinical care
  • 2007 Fellowship of the Academy of Medical Sciences
  • 2007 Spinoza Visiting Professorship, University of Amsterdam
  • 2006 Royal College of Physicians Jean Hunter Prize for research into nervous disorders
  • 2004 Invited Fellowship of the American Neurological Association
  • 2001 American Academy of Neurology and ALS Association Sheila Essey Award for outstanding research contribution in amyotrophic lateral sclerosis/ motor neurone disease
  • 2000 Hong Kong Neurological Association Li Po Shan/ Dr Vincent Liu visiting Professorship
  • 1997 Invited Fellowship of the American Academy of Neurology
  • 1996 Renewal of Wellcome Senior Fellowship in Clinical Science
  • 1995 British Medical Association Vera Down Award
  • 1992 Poster Research prize at the Third International Symposium on ALS/MND
  • 1991 Award of Wellcome Senior Fellowship in Clinical Science
  • 1991 Association of British Neurologists Sir Charles Symonds Prize
  • 1990 North of England Neurological Association Liversedge Research Prize
  • 1985 Northern Regional Health Authority David Dickson Research Prize
  • 1985 Association of Physicians UK Dewar Research Prize
  • 1985 British Cardiac Society Young Investigator of the Year award

Research Interests

Professor Shaw’s research is focused on 3 main goals:

  1. To understand the function of motor neurons in health and disease and to translate basic science findings into health benefits for patients with degenerative motor system disorders.
  2. To provide excellent clinical care for patients with motor system disorders, at all disease stages incorporating: multidisciplinary team working, evidence based standards of care for symptomatic management, and evaluation of new neuroprotective therapies.
  3. To foster excellent training for clinical and scientific junior staff with the aim of ensuring high standards of future care and linking new developments in medical science firmly to the needs of patients with neurological disorders.

Since 1983 she has supervised the research training of > 120 individuals from medicine and science including 45 PhD/MD students.

Current Projects

Professor Shaw is a Clinician Scientist in Neurology, an NIHR Senior Investigator and formerly a Wellcome Senior Clinical Fellow. Supported by long-term programme funding from the Wellcome Trust, she has since 1991 led a major multidisciplinary programme of research investigating genetic, molecular and neurochemical factors underlying neurodegenerative disorders of the human motor system. Her team use robust cellular and in vivo models of neurodegeneration and correlate key findings with disease related changes in the human nervous system. Significant research achievements include:

  1. Identification of cell specific features of motor neurons which underlie susceptibility to neurodegeneration.
  2. Understanding the cellular pathways of motor neuron injury in the presence of mutant SOD1 using a combination of cell biology, proteomics and gene expression profiling.
  3. Identifying the different subtypes of motor neuron disease (MND) based on genetics and molecular pathology.
  4. Development of new small molecule and gene therapy candidate treatments for patients using staged screening programmes in cellular and other experimental model systems.
  5. Promoting the introduction of one neuroprotective drug for MND into clinical practice – riluzole.
  6. Establishing the role of non-invasive ventilation (NIV) in improving the quality of life and prolonging survival of MND patients.

Professor Shaw’s research is currently funded by the Medical Research Council, NIHR, the Motor Neurone Disease Association, the European Union and biotechnology & pharmaceutical industry partners. Since 1983 she has generated more than £56m in research income.

Professional Activities

Professor Shaw is a member of multiple national and international committees, sits on the editorial board of several journals including Brain and Amyotrophic Lateral Sclerosis and is a reviewer for numerous other journals.

Membership of Editorial Boards

  • Muscle and Nerve
  • Editorial Panel for Research Frontiers in Science, British Medical Journal.
  • Editorial board of Amyotrophic Lateral Sclerosis & Frontotemporal Dementia
  • Editorial Board of Brain

She has been a research advisory panel member for the Wellcome Trust, MNDA, MRC,the Muscular Dystrophy Association the Academy of Medical Sciences, the Acade,my of Scienec Finland and reviews for multiple grant awarding bodies.

Membership of National and International Committees

  • Member of the Executive Committee of the Association of Physicians of Great Britain and Ireland from 1996 to 1999.
  • Member of the Motor Neurone Disease Research Advisory Panel from1993 to 1997.
  • Member of the Association of British Neurologists Clinical Research and Academic Committee from 1998 - 2007.
  • Guarantor of the Brain Trust from 1998 - present.
  • Advisor to the Department of Health Medicines Control Agency/ Committee on Safety of Medicines from 1997 - present.
  • Wellcome Trust / Irish Health Board New Blood Fellowship panel from 1998 - 2000.
  • External assessor for Parkinson’s Disease Society 2000.
  • Medical Advisor to the Motor Neurone Disease Association 2000 - present.
  • Member of the Neurosciences Subpanel for the 2001 Research Assessment Exercise.
  • Member of the Medical Research Society Committee from 2001 - 2004.
  • Invited expert participant in the NICE panel for the evaluation of riluzole therapy 2001.
  • Member of Council for the Association of British Neurologists from 2001 - 2007.
  • Chair of the Association of British Neurologists Clinical Research and Academic Committee from 2001 -2007.
  • Member of the Wellcome Trust Neurosciences Panel from 2001 - 2004.
  • Member of Meetings Subcommittee of the Association of British Neurologists from 2001-2003.
  • Invited external Neuroscience assessor for Universities of Glasgow and UCL 2003.
  • Member of the Research Advisory panel for the Muscular Dystrophy Campaign 2004-2007.
  • Member of the Medical Research Council College of experts 2005-2010.
  • Advisory Board for Oxford Biomedica from 2005 - 2009.
  • Member of HEFCE Clinical Senior Lecturer Appointments Panel 2006 -2009.
  • Associate Director and Chair of the Motor Neuron Disease Clinical Studies Group UKCRN Dementia and Neurodegenerative Diseases Clinical Research Network 2006 – present.
  • Member of NIHR Experimental Medicine Committee and Experimental Medicine Lead for DeNDRoN 2006 – 2010.
  • Academy of Medical Sciences Fellowship Panel 2007 – 2010.
  • Academy of Medical Sciences Clinical Academic Training Committee 2007 – 2010.
  • Wellcome Trust / Academy of Medical Sciences New Lecturer Awards panel from 2009 - 2011.
  • UKCRC/ MRC Brain Bank Strategy Advisory Committee 2007 – 2008.
  • Member of MRC strategic group for neurodegeneration 2008 - 2010.
  • Member of the Medical Research Council Neuroscience and Mental Health Board 2012 – present.
  • Academy of Medical Sciences INSPIRE Panel 2012 -2014
  • Chair of Progressive Supranuclear Palsy (PSP) Research Advisory Panel 2015 – present.
  • World Federation of Neurology Working Group on Therapeutic Trials in ALS/MND from 1996.
  • Founding Secretary to the European ALS Study Group from 1997 to 2000.
  • European ENCALS Steering Group 2002 – 2012.
  • Member of the European Neurological Society Scientific Committee on motor neurone disease from 1998 - 2006.
  • Coordinator of the Molecular/ Cell Biology Section of the European Familial ALS Group from 1997 to 2000.
  • External Assessor for the appointments committee for consultant posts in Neurology at the Beaumont Hospital, Dublin 1999.
  • Steering Committee ONO Pharmaceuticals from 2002 - 2005.
  • Chair of the Scientific Programme Committee for International MND/ALS annual scientific symposium 2004 –2010.
  • Novartis ALS/MND international advisory board, 2002 - 2003.
  • Member of the scientific panel for the European Federation of Neurological Societies (EFNS) 2004 -2006.
  • Member of the scientific panel and organising committee for the XI International Congress on Neuromuscular disorders 2004 -2006.
  • Princes Beatrijs Fonds Neuroscience Panel The Netherlands 2006.
  • Irish Health Research Board Clinician Scientist review panel 2010.
  • Member of the Executive Committee of the European Network for the Cure of ALS (ENCALS) 2012 – present.
  • Member of the Academy of Science Finland Neuroscience Grant panel 2013 – 2014. Chair 2014.
  • UK Lead for the Biogen ALS Innovation Hub 2015 – present.
  • Member of the Scientific Committee for the European Neuromuscular Centre (ENMC) 2015 - 2016

Principal Funding Sources

  • The Wellcome Trust
  • The Motor Neurone Disease Association
  • The Medical Research Council
  • NIHR
  • European Union

Research Teams

Current Scientific research team

Adrian Higginbottom
Paul Heath
Johnathan Cooper-Knock
James Alix
Rachel Waller
Stephanie Shepheard
Esther Hobson
Heledd Brown-Wright
Joseph Scarrott
Matthew Shaw
Yuri Cervio
Noemi Gatto
Chloe Allan
Llewellyn Griffiths

SITraN PI Scientific Collaborators

Laura Ferraiuolo
Robin Highley
Richard Mead
Janine Kirby
Scott Allen
Guillaume Hautbergue
Stuart Wilson
Winston Hide

Current Clinical Research Team

Hannah Hollinger
Theresa Walsh
Helen Wollff
Mbombe Kazoka
Lee Tuddenham
Haris Stavroulakis
James Alix
Stacy Young
Johnathan Cooper-Knock
Esther Hobson

SITraN PI Clinical Research Collaborators

Chris McDermott
Tom Jenkins

PUBLICATIONS >425 H-INDEX 82

Selected Recent Publications

Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomized controlled trial. SC Bourke, M Tomlinson, TL Williams, RE Bullock, PJ Shaw*, GJ Gibson* (Joint Senior Authors). Lancet Neurology 5:140-147;2006.


Pathogical TDP-43 distinguishes sporadic ALS from ALS with SOD1 mutations. IRA Mackenzie, EH Bigio, PG Ince, F Geser, M Neumann, NJ Cairns, LK Kwong, MS Forman, J Ravits, H Stewart, A Eisen, L McClusky, HA Kretzschmar, CM Monoranu, R Highley, J Kirby, T Siddique, PJ Shaw, VMY Lee, J Q Trojanowski. Ann Neurol 61:427-435;2007.


Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. L Ferraiuolo, PR Heath, H Holden, PR Kasher, J Kirby, PJ Shaw. J Neuroscience 27:9201-9219;2007.


Physical exercise as an exogenous risk factor in motor neurone disease (MND): a review of the evidence. C Moore, CJ McDermott, PJ Shaw. Amyotrophic Lateral Sclerosis 2009;4:1-14.


Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). LE Cox, L Ferraiuolo, PR Heath, A Higginbottom, H Mortiboys, H Nixon, JA Hartley, A Brockington, CE Burness, SB Wharton, AJ Grierson, PG Ince, J Kirby, PJ Shaw. PloS One 5: e9872 ;2010 (ePub March 24)


Oxidative stress in ALS: key role in motor neuron injury and a therapeutic target. SC Barber, PJ Shaw. Free Rad Biol Med 48:629-641;2010.


Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. VM Van Deerlin, PMA Sleiman, M Martinez-Lage et al including PJ Shaw Nature Genetics 42:234-239; 2010.


PTEN depletion modulates axon growth and regulates translation of β-actin at the growth cone in motor neurons. K Ning, C Drepper, C Valori, M Wyles, A Higginbottom, T Hermann, PJ Shaw, M Azzouz, M Sendtner. Hum Mol Genet 19:3159-3168;2010.


Systemic delivery of sc AAV9 expressing SMNB prolongs survival in a model of spinal muscular atrophy. CF Valori, K Ning, M Wyles, RJ Mead, AJ Grierson, PJ Shaw, M Azzouz. Science Translational Medicine 2010 Jun9:2:35ra42.


Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer’s pathology and the APOE genotype. JE Simpson, PG Ince, PJ Shaw, PR Heath, R Raman, C Gelsthorpe, L Baxter, G Forster, FE Matthews, C Brayne, SB Wharton on behalf of the MRC Cognitive Function and Ageing Neuropathology Group. Neurobiol Aging 32:1795-1807;2011.


PTEN/AKT pathway linked to motor neuron survival in human SOD1-related amyotrophic lateral sclerosis (ALS). J Kirby*, K Ning*, L Ferraiuolo, PR Heath, A Ismail, S-W Kuo, L Cox, CF Valori, LE Cox, B Sharrack, SB Wharton, PG Ince, PJ Shaw*, M Azzouz*. Brain 134:506-517;2011 (*Equal contribution).


Dysregulation of astrocyte-motor neuron cross-talk in mutant SOD1 related amyotrophic lateral sclerosis. L Ferraiuolo, A Higginbottom, PR. Heath, S Barber, D Greenald, J Kirby & PJ. Shaw. Brain 134:2627-2641; 2011.


Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. L Ferraiuolo, J Kirby, AJ Grierson, M Sendtner, PJ Shaw. Nature Reviews Neurology 7:616-630; 2011.


Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. J Cooper-Knock*, C Hewitt*, J R Highley*, A Brockington, A Milano, S Man, et al, PG Ince, J Hardy, PJ Shaw. *Equal contribution. Brain 135:751-764;2012.


The natural history of motor neuron disease: assessing the impact of specialist care. T Aridegbe, R Kandler, T Walsh, PJ Shaw*, CJ McDermott*. Equal contribution. Amyotroph Lateral Scler Frontotemporal Degen 2012 (Epub May 29). d.o.i: 10.3109/17482968.2012.690419; PMID:22642305.


Gene expression profiling in human neurodegenerative disease. J Cooper-Knock, J Kirby, L Ferraiuolo, PR Heath, M Rattray, PJ Shaw. Nature Reviews Neurology 8:518-530; 2012.


S[+] Apomorphine is a CNS penetrating activator of the NRF2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. RJ Mead, A Higginbottom, E Bennett, J Kirby, E Bennett, SC Barber, SP Allen, PR Heath, A Coluccia, A Brancale, AJ Grierson, PJ Shaw. Free Rad Biol Med 61C: 438-452; 2013.


Lithium in patients with Amyotrophic lateral sc lerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. [Eudract number: 2008-006891-31]. UKMND-LiCALS* Group including PJ Shaw as PI. Lancet Neurology 12:339-345;2013 (EPub Feb 27). d.o.i: 10.1016/S1474-4422(13)700374; PMID:23453347.


Unravelling the enigma of selective vulnerability in neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression characteristics and decreased susceptibility to excitotoxicity. A Brockington, K Ning, PR Heath, E Wood, N Fusi, N Lawrence, PG Ince, SB Wharton, PG Ince, PJ Shaw. Acta Neuropath 125:95-109; 2013.


Whole genome transcriptome analysis identifies indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. G Nardo, R Iennaco, N Fudi, N Lawrence, M Marino, P Heath, L Ferraiuolo, PJ Shaw**, C Bendotti**. Equal contribution. Brain 136:3305-3332;2013.


A new zebrafish model of SOD1 ALS produced by TILLING replicates key features of the disease and represents a tool for in vivo therapeutic screening. MMJ Da Costa, CE Allen, A Higginbottom, T Ramesh, PJ Shaw*, CJ McDermott*. Equal contribution. Disease Models and Mechanisms 2013 (EPub 2 October). d.o.i: 10.1242/dmm.012013 PMID:24092880. 290.


Early interneuron dysfunction in ALS: Insights from a mutant sod1 zebrafish model. A McGown, A Al Mashadi, N Redhead, A Lyon, CE Beattie, PJ Shaw, T Ramesh. Ann Neurol 73:246-258;2013 (E pub Oct 1 2012). D.o.i: 10.1002/ana.23780. PMID:23281025.


Sequestration of multiple RNA recognition motif proteins by C9ORF72 GGGGCC expanded repeats in amyotrophic laterals sclerosis. M J Walsh, J Cooper-Knock, A Higginbottom, JR Highley, J Bury, M Dickman, M Rattray, PR Heath, M Wyles, S Wharton, PG Ince, S Wilson, J Kirby, GM Hautbergue, PJ Shaw. Brain 137:2040-2051; 2014.


A zebrafish model exemplifies the long pre-clinical period of motor neuron disease. TM Ramesh, PJ Shaw, J McDearmid. J Neurol Neurosurg Psychiatry 85:1288-1289;2014 (EPub Jun 26). PMID 24970908.


Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. K Meyer, L Ferraiuolo, CJ Miranda, S Likhite, S McElroy, S Renusch, D Ditsworth, C Lagier-Tourenne, RA Smith, J Ravits, AH Burghes, PJ Shaw, DW Cleveland, SJ Kolb, BK Kaspar. PNAS 111:829-832;2014. PMID: 24379375.


PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy. D Little, CF Valori, CA Mutsaers, EJ Bennett, M Wyles, PJ Shaw, TH Gillingwater, M Azzouz, K Ning. Molecular Therapy 2014 (ePub November 5). PMID: 25369768


Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. BT Smith1, N Ticozzi, C Fallini, A Soragia Gkazi, S Topp, J Kost, E Scotter, P Keagle, J Miller, C Tiloca, C Vance, EW Danielson, C Troakes, C Colombrita, S Al-Sarraj, EA Lewis, A King, D Calini, V Pensato, B Castellotti, J de Belleroche, F Bass, AALM ten Asbroek, KP Kenna, RL McLaughlin, M Polak, S Asress, J Esteban-Pérez, JL Muñoz-Blanco, SLAGEN Consortium, G Lauria, S Duga, S Corti, C Cereda, C Lucia, G Sorarù, O Hardiman, KE Morrison, A Al-Chalabi, H Pall, PJ Shaw, K Talbot, F Taroni, A García-Redondo, Z Wu, JD Glass, C Gellera, A Ratti, V Silani, CE Shaw, JE Landers. Neuron 84:324-331;2014.


Gastrostomy in patients with amyotrophic lateral sclerosis (ProGAS): a prospective cohort study.motor neurone disease. ProGas Study Group including PJ Shaw as Co-Chief Investigator. Lancet Neurology 14:702-709; 2015. PMID:26027943.


Antisense RNA foci in the motor neurons of C9ORF72- ALS are associated with TDP-43 proteinopathy. J Cooper-Knock, A Higginbottom, MJ Stopford, JR Highley, PG Ince, SB Wharton, S Pickering-Brown, J Kirby[, GM Hautbergue, PJ Shaw. Acta Neuropathologica 130:63-75;2015.


ZNStress: A high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis. A McGown, PJ Shaw, T Ramesh. Molecular Neurodegeneration 2016 (In Press).


The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. CP Webster, EF Smith, CS Bauer, GM Hautbergue, L Ferraiuolo, M Myszczynska, A Higginbottom, MJ Walsh, A Moller, AJ Whitworth, BK Kaspar, K Meyer, PJ Shaw, AJ Grierson, KJ De Vos. EMBO J 2016;35:1656-1676. PMID: 27334615.


Oligodendrocytes contribute to motor neuron death in ALS via SOD1 dependent mechanism. L Ferraiuolo, K Meyer, T Sherwood, J Vick, S Likhite, AE Frakes, C Miranda, L Braun, PR Heath, R Pineda, CE Beattie, PJ Shaw, C Askwith, DM McTigue, B K Kaspar. PNAS 2016 Sept 29 PMID:27688759.


Long-term physical activity: an exogenous risk factor for sporadic amyotrophic lateral sclerosis. CA Harwood, H Besson, U Ekelund, K Westgate, S Gunstone, S Brage, S Sharpe, NJ Wareham, CJ McDermott, PJ Shaw. Amyotroph Lateral Scler Frontotemporal Degener. 2016 (E pub March 2016).


Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. W van Rheenen, A Shatunov, AM Dekker, et al. Nature Genetics 2016 48:1043-1048. PMID:27455348.


NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. KP Kenna, PTC van Doormaal, A Dekker, et al. Nature Genetics 2016; 48:1037-1042. PMID: 27455347.


Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. ET Cirulli, BN Lasseigne, S Petrovski, PC Sapp, PA Dion, CS Leblond, J Couthouis, Y‐Fan Lu, Q Wang, BJ Krueger, Z Ren, J Keebler, Y Han, SE Levy, BE Boone, JR Wimbish, LW Jones, AL Jones, JP Carulli, A Day-Williams, JF Staropoli, WW Xin, A Chesi, AR Raphael, D McKenna-Yasek, J Cady, JMBV de Jong, KP Kenna, BN Smith, S Topp, J Miller, A Gkazi, FALS Sequencing Consortium including PJ Shaw, A Al-Chalabi, LH van den Berg, J Veldink, V Silani, N Ticozzi, CE Shaw, RH Baloh, S Appel, E Simpson, C Lagier-Tourenne, SM Pulst, S Gibson, JQ Trojanowski, L Elman, L McCluskey, M Grossman, NA Shneider, WK Chung, JM Ravits, JD Glass, KB Sims, VM Van Deerlin, T Maniatis, SD Hayes, A Ordureau, S Swarup, J Landers, F Baas, AS Allen, RS Bedlack, J Wade Harper, AD Gitler, GA Rouleau, R Brown, MB Harms. Science 347:1436-1441;2015. PMID 25700176.


A randomised controlled trial of the effectiveness of the NeuRx RA/4 Diaphragm Pacing System in patients with respiratory muscle weakness due to motor neurone disease (DiPALS). DiPALS Writing Group; DIPALS Study Group Collaborators including PJ Shaw as Sheffield Centre PI. Lancet Neurology 14:883-892; 2015. PMID:26234554.


C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons. Sivadasan R, Hornburg D, Drepper C, Frank N, Jablonka S, Hansel A, Lojewski X, Sterneckert J, Hermann A, Shaw PJ, Ince PG, Mann M, Meissner F, Sendtner M. Nature Neuroscience. 2016 Oct 10. PMID: 27723745.


C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten. M Stopford, A Higginbottom, G Hautbergue, J Cooper-Knock, P Mulchay, K de Vos, M Azzouz, PR Heath, J Kirby, PJ Shaw. Human Molecular Genetics 2017 (In Press).


A data-driven approach reveals microglial activity to predict pathology and prognosis in amyotrophic lateral sclerosis. J Cooper-Knock, C Green, G Altschuler, W Wei, JJ Bury, PR Heath, M Wyles, C Gelsthorpe, JR Highley, A Pons, K Doyle, K Otero], B Traynor, J Kirby, PJ Shaw*, W Hide*. *Equal contribution. Acta Neuropath Communications 2017 (In Press).